Dana-Farber Research Advances Lead to FDA Label Update for Primary CNS Lymphoma
In a groundbreaking advancement for the treatment of central nervous system (CNS) lymphoma, the U.S. Food and Drug Administration (FDA) ...
Tag: Dana-Farber Cancer Institute research
Antibody-Drug Conjugates Enhance Outcomes in Advanced Triple-Negative Breast Cancer Patients Unsuitable for Immune Checkpoint Inhibitors
In a groundbreaking advancement in the treatment of aggressive breast cancers, researchers have unveiled promising results from the ASCENT-03 trial, ...
Combination Chemotherapy Enhances Overall Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
In a groundbreaking advancement in the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) ...
Dana-Farber Unveils Innovative Diagnostic Tool Transforming Acute Leukemia Detection
In a groundbreaking advancement poised to revolutionize acute leukemia diagnosis and treatment, researchers at the Dana-Farber Cancer Institute have unveiled ...
Study Reveals Impact of Diet on Survival Rates in Stage III Colon Cancer Patients
A groundbreaking new analysis from Dana-Farber Cancer Institute highlights a significant link between diet, physical activity, and survival outcomes in ...
EQUAL Study Initiates Lung Cancer Screening Trial Targeting High-Risk Individuals
A groundbreaking clinical study spearheaded by researchers at the Dana-Farber Cancer Institute in Boston is embarking on an innovative quest ...
Dana-Farber Nurses Showcase Groundbreaking Research at 2025 Oncology Nursing Society Congress
Nurses have always played a pivotal role in the healthcare system, especially in oncology, where they serve not just as ...
Revolutionary Genomic Screening Tool Facilitates Precision Reverse-Engineering of Cellular Genetic Programming
In an extraordinary advancement for the field of genetics, researchers associated with the Dana-Farber Cancer Institute have unveiled a groundbreaking ...
FDA Grants Approval for Innovative Dual-Action Therapy Targeting Previously Treated Advanced Neuroendocrine Tumors, Supported by Dana-Farber Research
Cabozantinib, an innovative oral tyrosine kinase inhibitor, has recently received approval from the U.S. Food and Drug Administration (FDA) for ...
Promising Targeted Therapy for Pediatric Brain Cancer Discovered by Dana-Farber Researchers
Boston, Massachusetts, has become the epicenter of groundbreaking cancer research following the results of a novel clinical trial that evaluated ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!